| Targeting CD38 with daratumumab in refractory systemic lupus erythematosus L Ostendorf, M Burns, P Durek, GA Heinz, F Heinrich, P Garantziotis, ... New England Journal of Medicine 383 (12), 1149-1155, 2020 | 228 | 2020 |
| Sialic acid–binding Ig‐like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in … R Biesen, C Demir, F Barkhudarova, JR Grün, M Steinbrich‐Zöllner, ... Arthritis & Rheumatism 58 (4), 1136-1145, 2008 | 224 | 2008 |
| CXCR3+ CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients P Enghard, JY Humrich, B Rudolph, S Rosenberger, R Biesen, A Kuhn, ... Arthritis & Rheumatism 60 (1), 199-206, 2009 | 189 | 2009 |
| IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus T Rose, A Grützkau, H Hirseland, D Huscher, C Dähnrich, A Dzionek, ... Annals of the rheumatic diseases 72 (10), 1639-1645, 2013 | 150 | 2013 |
| Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference? C Kyogoku, B Smiljanovic, JR Grün, R Biesen, U Schulte-Wrede, T Häupl, ... PloS one 8 (12), e83776, 2013 | 91 | 2013 |
| The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines B Smiljanovic, JR Grün, R Biesen, U Schulte-Wrede, R Baumgrass, ... Journal of molecular medicine 90, 1295-1309, 2012 | 84 | 2012 |
| Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors T Alexander, Q Cheng, J Klotsche, L Khodadadi, A Waka, R Biesen, ... European journal of immunology 48 (9), 1573-1579, 2018 | 80 | 2018 |
| Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response P Enghard, C Rieder, K Kopetschke, JR Klocke, R Undeutsch, R Biesen, ... Annals of the rheumatic diseases 73 (1), 277-283, 2014 | 79 | 2014 |
| Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function V Gerl, A Lischka, D Panne, P Großmann, R Berthold, BF Hoyer, R Biesen, ... Annals of the rheumatic diseases 69 (7), 1370-1377, 2010 | 77 | 2010 |
| Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study T Rose, A Grützkau, J Klotsche, P Enghard, A Flechsig, J Keller, ... Rheumatology 56 (9), 1618-1626, 2017 | 64 | 2017 |
| The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity D Medgyesi, E Hobeika, R Biesen, F Kollert, A Taddeo, RE Voll, F Hiepe, ... Journal of Experimental Medicine 211 (3), 427-440, 2014 | 64 | 2014 |
| The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers K Kopetschke, J Klocke, AS Grießbach, JY Humrich, R Biesen, D Dragun, ... Arthritis research & therapy 17, 1-9, 2015 | 61 | 2015 |
| SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome T Rose, F Szelinski, A Lisney, K Reiter, SJ Fleischer, GR Burmester, ... RMD open 2 (2), e000292, 2016 | 58 | 2016 |
| Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis F Weigold, J Günther, M Pfeiffenberger, O Cabral-Marques, E Siegert, ... Arthritis research & therapy 20, 1-9, 2018 | 54 | 2018 |
| Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus R Biesen, C Dähnrich, A Rosemann, F Barkhudarova, T Rose, O Jakob, ... Arthritis research & therapy 13, 1-9, 2011 | 50 | 2011 |
| CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity JM Doehn, C Tabeling, R Biesen, J Saccomanno, E Madlung, E Pappe, ... Infection 49, 757-762, 2021 | 47 | 2021 |
| Choose wisely: imaging for diagnosis of axial spondyloarthritis T Diekhoff, I Eshed, F Radny, K Ziegeler, F Proft, J Greese, D Deppe, ... Annals of the rheumatic diseases 81 (2), 237-242, 2022 | 46 | 2022 |
| Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases ANA de Silva, LM Frommert, FN Albach, J Klotsche, V Scholz, ... Annals of the rheumatic diseases 81 (6), 881-888, 2022 | 42 | 2022 |
| What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3 A Flechsig, T Rose, F Barkhudarova, R Strauss, J Klotsche, C Dähnrich, ... Clin Exp Rheumatol 35 (4), 598-606, 2017 | 41 | 2017 |
| From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases M Steinbrich‐Zöllner, JR Grün, T Kaiser, R Biesen, K Raba, P Wu, A Thiel, ... Cytometry Part A: The Journal of the International Society for Analytical …, 2008 | 37 | 2008 |
Thomas RoseArztVerified email at charite.de
